Northwest Biotherapeutics, Inc. (NWBO) Launches Cross-country Enrollment for Promising Brain Cancer Treatment
Northwest Biotherapeutics, a biotech company focused on immunotherapy products to treat cancer without toxicities associated with chemotherapies, today announced it has begun enrollment of new patients in the company's ongoing 240-patient randomized, double blind, placebo controlled clinical trial of DCVax® immune therapy for Glioblastoma multiforme (GBM), the most fatal type of brain cancer. So far the company has enrolled 33 patients for the cancer trial and its information arm; patients are already receiving treatment regimen and follow-up. Four recruiting centers are carrying out the company’s enrollment initiatives: the University of Rochester in New York; the University Hospitals of Cleveland in…